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Presentation {#sec0001}
============

A 57-year-old woman from Wuhan, China, visited our hospital with a 5-day history of fever and dry cough. On the day of her visit, she presented with slight chest tightness, chills, and muscle soreness of the lower limbs.

Assessment {#sec0002}
==========

On examination, she was conscious with a body temperature of 38.3°C and her vital signs were stable. Small moist rales were heard in both lungs. Laboratory tests of her blood revealed 4.49 × 10^6^ white blood cells per μL, with increased proportion of neutrophils (78.1%) and decreased proportion of lymphocytes (18.0%). C-reactive protein was elevated to 73.4 mg/L. Chest computed tomography (CT) indicated multifocal ill-defined nodular ground-glass opacities ([Figure 1](#fig0001){ref-type="fig"} A, arrow) and patchy consolidations lesions (arrow head) distributed in the middle-lateral zone and subpleural regions. Tests for *Chlamydia pneumoniae, Mycoplasma pneumoniae*, respiratory syncytial virus (RSV), adenovirus and coxsackie virus, and influenza A and influenza B viruses were all negative, while quantitative real-time polymerase chain reaction (PCR) of the patient\'s sputum tested positive for 2019 novel coronavirus (2019-nCoV) nucleic acid.Figure 1**(A)** Chest computed tomography (CT) showed multifocal ill-defined nodular ground-glass opacities and patchy consolidations lesions distributed in the middle-lateral zone and subpleural regions. **(B)** Chest CT showed decreased extent and intensity of the lesions and irregular consolidation in the subpleural regions of the right lower lung. **(C)** Chest CT showed significantly decreased lesions.Figure 1

Diagnosis {#sec0003}
=========

CT findings together with a positive 2019-nCoV nucleic acid test led to a diagnosis of 2019-nCoV pneumonia (NCP). In December 2019, a kind of pneumonia with an unknown cause emerged in Wuhan, China, and the pathogen was soon identified as a previously unknown betacoronavirus.[@bib0001] Experts have confirmed that the virus was capable of spreading from human to human. The reported mortality ranged from 4.3% to 15%.[@bib0002], [@bib0003], [@bib0004]

Management {#sec0004}
==========

The patient received moxifloxacin (400 mg once daily intravenously for 8 days and then was switched to oral treatment), oseltamivir (75 mg twice daily orally for 5 days), and supportive therapy. The patient recovered with improved symptoms and, on treatment evaluation of chest CT obtained 7 days later, showed decreased extent and intensity of the lesions, although irregular consolidation ([Figure 1](#fig0001){ref-type="fig"}B, asterisk) emerged in the subpleural regions of the right lower lung. The patient was discharged after her body temperature returned to normal for at least 3 days and had 2 consecutive negative tests for 2019-nCoV nucleic acid. A repeat chest CT performed 10 days later showed significantly improved lesions ([Figure 1](#fig0001){ref-type="fig"}C). Currently, the patient is in follow-up care with favorable condition.
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